Rogiola 5 mg chewable tablets for dogs

Authorised

- Robenacoxib

Product identification

Medicine name:
Rogiola 5 mg chewable tablets for dogs
Rogiola Vet. 5 mg tyggetabletter

Active substance:
Robenacoxib

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Robenacoxib
5.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QM01AH91

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:
OPA/Al/PVC/Aluminium perforated blister containing 10 tablets: 10 x 1 chewable tablet in perforated unit dose blisters, in a cardboard box.
OPA/Al/PVC/Aluminium perforated blister containing 10 tablets: 30 x 1 chewable tablet in perforated unit dose blisters, in a cardboard box.
OPA/Al/PVC/Aluminium perforated blister containing 10 tablets: 60 x 1 chewable tablet in perforated unit dose blisters, in a cardboard box.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
8/11/2023

Manufacturing sites for batch release:
TAD Pharma GmbH

Krka-Farma d.o.o.
KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:
Danish Medicines Agency

Authorisation number:
69825

Date of authorisation status change:
8/11/2023

Reference member state:
Ireland

Procedure number:
IE/V/0785/001

Concerned member states:
Austria Belgium Cyprus Denmark Finland France Germany Greece Italy Netherlands Norway Portugal Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download